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3. Abbreviations 
AUC Area under the curve 
BIA 9-1067 Opicapone (Ongentys®) 
Cmax Maximal concentration 
COMT Catechol-O-methyltransferase 
L-dopa Levodopa 
MAO-B Monoamine oxidase B 
MCI Mild cognitive impairment 
NMSS  Non-Motor Symptom Scale 
PD Parkinson’s disease 
PDQ-39  39-item Parkinson’s Disease Questionnaire 
PDSS Parkinson’s Disease Sleep Scale 
RBD Rapid-eye movement behavioral sleep disorder 
REM Rapid-eye movement 
UDP Uridine 5'-diphospho  
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4. Abstract 
a. Introduction  
Parkinson’s disease (PD) is a relentless progressive neurodegenerative disease 
characterized by motor and non-motor symptoms. Unfortunately, at the present time, 
the only available treatment options have a symptomatic effect. Altough as the disease 
progresses almost all antiparkinsonian pharmacological classes are tried, the gold 
standard of pharmacological management is still L-dopa. Various strategies can be 
used to raise the dopaminergic tone among the basal ganglia. Catechol-O-
methyltransferase (COMT) inhibitors attain this goal mainly by decreasing L-dopa 
peripheral metabolism.  
b. Areas covered  
Opicapone (Ongentys®) is a newly designed COMT inhibitor developed to fulfil the 
need for more potent, safer and longer acting COMT inhibitors. This review puts into 
context the use of COMT inhibitors, in particular opicapone’s indications, its 
chemical and preclinical data, the pharmacodynamics and pharmacokinetic 
characteristics, and finally the efficacy and safety results delivered by clinical trials. 
c. Expert opinion  
Opicapone, also known as BIA 9-1067, is an efficacious COMT inhibitor. Its 
chemical, pharmacodynamics and pharmacokinetic proprieties make it adequate for a 
once a day oral dose regimen. It has proved to reduce the off-time and to increase the 
on-time without troublesome dyskinesias in PD patients with motor fluctuations. The 
reported adverse events suggest an overall safe and well-tolerated profile.  
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The most common adverse events were dyskinesia and there were no issues of 
concern for hepatotoxicity, severe diarrhoea or chromaturia. 
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5. Keywords 
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6. Introduction 
Parkinson’s disease (PD) is a multifaceted neurodegenerative condition with a 
relentless natural course and results from an intricate interplay between nature and 
nurture.[1] It affects each 3 in 1,000 people in the world[2] and is characterized by 
progressive motor and non-motor symptoms. 
Intracellular aggregation of alfa-synuclein and consequent formation of Lewy bodies 
and Lewy neuritis throughout the nervous system is one of the pathological hallmarks 
of PD.[3] 
The very particular result of this occurrence in basal ganglia is thought to lead to 
dopaminergic neuronal cell loss at substantia nigra pars compacta with a subsequent 
fall on cortical dopaminergic input.[4] This phenomenon is likely responsible for the 
detrimental classical parkisonian motor symptoms, including bradykinesia, rigidity 
and rest tremor.[5] 
Still, neuronal loss is widespread along the nervous system and determines non-motor 
symptoms.[4] A great focus has been put on these symptoms due to their burden [6] 
and specific time course.[7] The premotor phase of the disease can be remarkable for 
constipation, rapid-eye movement (REM) behavioral sleep disorders (RBD), 
hyposmia and depression[8] whereas in the motor phase PD is also accompanied by 
further autonomic dysfunction – urinary incontinence or retention, orthostatic 
hypotension, sexual dysfunction, hyperhidrosis –, psychosis, cognitive impairment – 
such as mild cognitive impairment (MCI) followed by dementia –, skin disturbances, 
among others.[9] 
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The clinical management is purely symptomatic, since no therapeutic strategy – either 
pharmacologic or not – has proven to regress, halt or decelerate disease 
progression.[10, 11] 
However, treatment of motor and non-motor symptoms can have a significant impact 
on patient health status. Direct and indirect dopamine enhancing agents are the 
mainstay of pharmacologic symptomatic therapy for motor symptoms. This group of 
drugs includes: L-dopa, dopamine agonists, monoamine oxidase B (MAO-B) 
inhibitors and catechol-O-methyltransferase (COMT) inhibitors.[12] Furthermore, 
functional neurosurgery and specific physiotherapy interventions are also beneficial 
for a subset of patients.[12] 
By means of reducing L-dopa metabolism, COMT inhibitors amplify L-dopa’s half-
life, and consequently its therapeutic effect duration. As such, they are only useful 
clinically as an add-on drug to L-dopa and never as a monotherapy.  
This class of drugs has shown little benefit when treating parkinsonism in early stage 
PD patients and preventing motor complications [13, 14, 15, 16] but substantial 
improvement was attained in reducing the off-time in more advanced PD.[17, 18, 19, 
20, 21, 22, 23] 
Still, the only available COMT inhibitors for medical use – entacapone and tolcapone, 
both second generation COMT inhibitors – have some weaknesses: entacapone 
requires frequent administrations (with each L-dopa intake) and has mild potency, and 
tolcapone, although a more potent and longer acting COMT inhibitor, obliges 
repeated liver function monitoring due to the risk of hepatotoxicity.[23] 
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Opicapone (Ongentys®), a third generation COMT inhibitor, designed to cover the 
drawbacks of others compounds from the same group, was granted market 
authorization in June 2016 by the Committee for Medicinal Products for Human Use, 
European Medicines Agency.  
The aim of this paper is to review the current evidence regarding opicapone’s 
pharmacological proprieties, efficacy and safety for the treatment of PD. 
 
a. Review criteria 
All published studies on opicapone were included and hierarchised by grade of 
evidence. The references were retrieved from EMBASE, Medline and CENTRAL 
using the terms “opicapone” and “BIA 9-1067”. Reference lists were cross-checked. 
The last search was conducted on February 2016. No language, time or quality 
restriction was applied. 
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7. Body of review 
a. Overview of the market 
Nowadays’ PD management is multidisciplinary and involves neurologists, 
psychiatrist, psychologists, neurosurgeons, nurses, physiotherapists, speech-language 
therapists, occupational therapists, social workers, nutritionists, sex therapists, among 
others.[24, 25] 
In the early stage of this dopamine deficiency state, the best strategy for the beginning 
of the pharmacological treatment is hill defined, and disability, handicap and 
treatment objectives should be weighted. The first-line drug groups for motor 
symptoms are MAO-B inhibitors, L-dopa and dopamine agonists.[24] L-dopa is the 
most efficacious drug, but longstanding use is associated with motor and non-motor 
fluctuations and dyskinesia.[24] 
As the disease advances, motor and non-motor symptoms evolve and aggravate, and 
other drug classes may have to be used, such as anti-psychotics, cholinesterase 
inhibitors.[25]   
Although the vast drug armamentarium available for PD management, L-dopa –
induced motor complications remain a key unmet need.[26] Indeed, about 40% of 
patients experience motor fluctuation after 4-6 years of L-dopa therapy.[27] Several 
strategies aiming to maintain a stable striatal dopaminergic tone over time are being 
develop, including new formulations and modes of delivery of L-dopa and 
apomorphine, adenosine antagonists, glutamatergic antagonists, and serotonergic 
drugs. [26] 
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Dopamine is the neurotransmitter critically involved in the physiology of motor 
symptoms: cortical loss of striatal tone. The exogenous replacement of this 
catecholamine is the mainstay of L-dopa treatment. This prodrug is the biological 
precursor of dopamine, but it is extensively metabolized in peripheral tissues before 
arriving to the brain, where it is transformed in dopamine by decarboxylation. As 
such, L-dopa is administrated together with a peripheral amino acid decarboxylase 
inhibitor – as carbidopa or benserazide -, preventing the breaking down of this 
catecholamine precursor[28] before trespassing the blood-brain barrier and increasing 
L-dopa bioavailability. 
Furthermore, COMT is a ubiquitous intracellular enzyme also involved in the 
peripheral tissues’ L-dopa catabolism. It mediates the transformation of L-dopa to 3-
O-methyldopa - an agent known to aggravate parkinsonism[29] - by transferring a 
methyl group from S-adenosyl-L-methionine to catecholic substracts.[30] When this 
enzyme is inhibited by COMT inhibitors, it has been found that L-dopa delivery to 
and availability in the central nervous system are superior and more stable.[31, 32] 
Correspondingly, L-dopa plasma half-life increases.[31]  
Currently there are two COMT inhibitors in the market: entacapone and tolcapone, 
both with practical limitations, as explained earlier.[23] This justified the research 
efforts put into the development of new, third generation, COMT inhibitor: 
nebicapone and opicapone. Nebicapone development program was discontinued due 
to safety concerns on hepatotoxicity.[33]  
b. Introduction to the compound 
Opicapone, also known as BIA 9-1067, is a hydrophilic, 1,2,4-oxadiazole analogue 
with a pyridine N-oxide residue at position 3. It is a competitive COMT inhibitor with 
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a long-acting inhibitory profile and its inhibitory effects are felt essentially in 
peripheral tissues, and in a reversible way. It was tailored-designed to be taken orally 
and once a day. [34] 
Opicapone chemical name is 2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl]-1,2,4-
oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide (Figure 1).[33]   
Its market name is Ongentys® and is currently licensed by the European Medication 
Agency. It has already been launched in the United Kingdom and Germany. 
 
c. Chemistry and preclinical data 
Opicapone is a heterocyclyl nitrocatechol derivative that evolved after structure-
activity studies. The first COMT inhibitors posing heterocyclic rings at the meta-
position relative to the nitro group were described in 1989.[35] Although having low 
toxicity in mice, their minor in vivo efficacy precluded clinical application. In 2010, 
Kiss et al. reported an optimization process for the former compounds.[34] Primarily, 
they substituted the trihydroxybenzene ring by a nitrocatechol subunit, generating a 
potent in vitro COMT inhibitor with less satisfactory in vivo characteristics. Then, a 
pyrazole ring was permuted by an oxadiazole ring, which provided a high in vivo 
potency to this molecule. Nonetheless, it was not sufficiently selective to peripheral 
tissue COMT and was vastly toxic. An extra replacement of the phenyl ring with 
heterocyclic rings produced meta-pyridyl-N-oxides with modest inhibitory potency 
and with little toxicity. Lastly, the pyridyl N-oxide ring was replaced by methyl and 
halogen, restoring the high potency and further dropping the toxicity, creating the 
opicapone molecule.[34] 
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Opicapone showed a high capacity of reducing COMT in rats and monkeys,[36, 37] 
and oral administration of opicapone in both animal models led to marked (>80%) but 
reversible inhibition of liver and kidney COMT without affecting COMT protein, 
RNA expression, or brain COMT.[36, 38, 39] The long-lasting effect of opicapone 
surpassed 24 hours and the enzymatic recovery took more than 28 hours.[37, 39] The 
maximal inhibitory effect was sustained over the first 8 hours.[40] Indeed, 
computational chemistry studies showed that opicapone has an exceptionally high-
binding affinity to human COMT: opicapone is a slowly reacting COMT substrate 
and the determinants of its high-inhibition potency are the catalytic rate of the 
inhibitor’s O-methylation rather than on the dissociation rate of the complex.[41]  
In rats, opicapone has been shown capable of achieving maximal COMT inhibition 
after 3-4 hours of oral administration and the inhibitory potency was proportional to 
the oral dose of opicapone.[34, 39]  
Comparing with tolcapone – the most potent COMT inhibitor used in clinical practice 
–, opicapone was found to be slightly more potent, and to increase by about 100% the 
L-dopa plasma levels and maintain these values for 24 hours.[34] 
Rat brain and liver homogenate studies showed that opicapone exercises a stronger 
and more sustainable COMT inhibition than tolcapone or entacapone: 99%, 82% and 
68% respectively after 1 hour of oral administration; and 91%, 16% and 
approximately zero after 9 hour of administration.[37] 
Opicapone catabolism involves conjugation to opicacone 3-O-glucuronide and 
opicapone 3-O-sulfate. Theses reactions take place in the liver and intestine and the 
main role-players are UDP-glucuronosyltransferases 1A7 and 1A9, and 
sulfotransferase 1A1, respectively for glucuronidation and sulfation.[42, 43] 
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Non-human primate and rat studies revealed that brain and blood bioavailability of L-
dopa duplicated after both single and chronic administration of opicapone, and 3-O-
metyldopa shrank to less than half.[36, 39, 40] The same studies demonstrated 
increased exposure of L-dopa in the dorsal striatum, substantia nigra and prefrontal 
cortex, and to dopamine in the brain matter in general. These results were not at the 
expense of a higher Cmax but of a greater AUC.  
In vitro human hepatocyte models compared opicapone, tolcapone and entacapone 
hepatotoxicity. Contrary to what was observed with tolcapone, opicapone did not 
compromised cell homeostasis and viability, an effect portrayed across growing 
doses.[44]  
 
d. Clinical development plan 
The clinical development plan of opicapone involved, so far, multiple phase I[45, 46, 
47], two phase II [48, 49] and two phase III trials (table 1).[50, 51]  
In 2013, Almeida L. and colleagues released the report of the first clinical study of 
opicapone in humans. This phase I dose-escalation and tolerability double-blind, 
randomized placebo-controlled clinical study intended to evaluate tolerability, 
pharmacokinetics and pharmadynamics after a single oral dose in healthy and young 
male individuals.[45]  
The same group conducted a further phase I, multiple-dose, dose-escalation and 
tolerability, double-blind, randomized placebo-controlled clinical to appraised 
tolerability, pharmacokinetics and pharmadynamics in healthy and young 
individuals.[46] 
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Rocha and colleagues conducted a phase 1, double-blind, randomized placebo and 
entacapone controlled clinical trial performed in a gender balanced population of 80 
healthy participants to study L-dopa opicapone-induced pharmacokinetics.[47]  
Multiple other phase I trials were conducted to test selected pharmacodynamic, 
pharmacokinetic, safety and tolerability aspects of opicapone, both on healthy 
volunteers and in niche groups, such as people with hepatic impairment and people on 
specific medications. 
The first phase II trial that tested opicapone was a multinational, multicenter, 
randomized, cross-over, double-blind, placebo-controlled trial of three single-dose 
regimens – 25, 50 and 100mg – on 10 patients with idiopathic PD on 
levodopa/carbidopa and with motor end-of-dose fluctuations. Pharmacokinetics was 
the primary outcome, but safety outcomes were also reported.[49] 
A second four-arm phase II, multinational, multicenter, randomized, parallel-group, 
double-blind, placebo-controlled trial by Ferreira JJ and colleagues compared 5, 15 
and 30mg of opicapone once daily with placebo during 28 day in 40 idiopathic PD 
patients on levodopa/carbidopa and with motor end-of-dose fluctuations. 
Pharmacokinetics was the primary outcome, but pharmacodynamics, efficacy, safety 
and tolerability were also studied.[48] 
Two phase III, multinational, multicenter, randomized, parallel-group, double-blind, 
placebo- and active-controlled studies – BIPARK-I and BIPARK-II – were conducted 
to evaluate the efficacy and safety of a once-daily dose of opicapone in addition to L-
dopa/carbidopa or L-dopa/benserazide in patients with end-of-dose motor 
fluctuations. Both studies included patients between 30 and 83 years-old with 
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idiopathic PD for at least 3 years, under 3-8 daily doses of L-dopa/DDCI and with 
end-of-dose wearing-off (end-of-dose deterioration).[50, 51]  
In BIPARK-I 600 patients from 20 European countries were randomized to opicapone 
(5mg, 25 mg or 50mg), placebo or entacapone (200mg) during 14 to 15 weeks. The 
primary end-point of this study was change in absolute off-time between baseline and 
the end of the evaluation period. This trial was designed to power a superiority 
comparison against placebo and a non-inferiority comparison against entacapone.[51] 
In BIPARK-II 407 patients from Europe, South America, Asia and Africa were 
randomized to opicapone (25 mg or 50mg) or placebo during 14 to 15 weeks. The 
primary end-point of this study was change in absolute off-time between baseline and 
the end of the evaluation period.[50, 52] 
After the blind-phase of BIPARK-I and BIPARK-II, keen subjects were allowed to 
enter an additional 1 year (52 weeks) open-label period of treatment with opicapone 
titrated to the most efficacious dose up to 50 mg maximum.  
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e. Pharmacodynamics 
Opicapone produces a marked and sustained COMT inhibition – as assessed using an 
erythrocyte COMT activity model. 
The inhibitory capacity of opicapone varies from 50% (5mg) to 100% (200mg and 
higher doses) and is attained 1 to 8 hours after oral dosing.[45, 46, 47, 48] 
This effect is long lasting and dose-dependent. Twenty-four hours after the last oral 
dose, the inhibition varied from 50% to 70% for opicapone doses ranging 5mg to 
30mg.[46, 48] The duration of effect is independent of the dose and the half-life of 
COMT inhibition is superior to 60 hours.[45] 
These effects can be explained by the high binding affinity of opicapone to COMT 
that translates into a slow complex dissociation rate constant.[41]  
Ferreira et al. demonstrated that 5mg of opicapone were capable of a maximal COMT 
inhibition of 52%, while 30mg could raise the inhibition up to 80%.[48] 
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f. Pharmacokinetics and metabolism 
Opicapone has a dose-proportional kinetics (first order kinetics).[45, 46] 
The time to reach maximum plasma concentration after oral administration is 
approximately 1.5-4 hours.[45, 46] The maximum plasma concentration is 
proportional to the administered dose[45, 46, 48] and significantly decreases if dosing 
is preceded by a high-fat high-caloric meal.[45] 
Studies in PD patients showed that 5, 15 and 30mg oral opicapone attain their 
maximal serum concentration at 2 hours and the its apparent half-life varies between 
0.9 and 1.6 hours.[48] 
Opicapone metabolism is entirely done via hepatic sulfation and elimination 
exclusively done by biliary excretion.[45, 46] No opicapone or its metabolites were 
ever quantified in urine.[45, 46] 
L-dopa pharmacokinetic profile studies in healthy subjects showed a significant 
increase in L-dopa minimal concentration, mean concentration and AUC without an 
increase in maximal concentration comparing opicapone treated arms with placebo 
arm. The AUC of entacapone (200mg) arm was significantly inferior to the one of 
opicaponde arm (50 and 75mg), leading to the conclusion that opicapone is superior 
to placebo and entacapone regarding L-dopa bioavailability.[47] In PD patients, 
opicapone (5, 15 and 30mg) increased L-dopa’s maximal concentration, area under 
the curve and half-life comparing with placebo.[48] The magnitude of AUC increase 
was 24,7%, 53,9% and 65,6% superior to placebo, respectively.[48] 
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Overall, these results point out that opicapone pharmacologic profile fits an orally 
formulation taken only once a day. They also suggest that dose adjustments have to be 
done in liver failure but not in kidney injury/disease. 
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g. Clinical efficacy 
Opicapone showed to be efficacious, safe and well tolerated across clinical trials. 
Ferreira et al., 2015 trial, although not designed or powered to detect differences in 
efficacy, showed a dose-dependent change in absolute off-time.[48] Patients on 
opicapone arm (5, 15 and 30mg) reported a decrease in off-time (16, 117 and 145 min 
per day, respectively) and an increase in on-time without troublesome dyskinesia (2, 
12 and 16%, respectively).[48]  
In BIPARK-I trial the mean change from baseline in off-time was -91.3 min for 5mg 
of opicapone, -85.9 min for 25 mg of opicapone, -116.8 min for 50mg of opicapone, -
96.3 min for 200 mg of entacapone and -56.0 min for placebo, respectively. The 
higher dose of opicapone was significantly different from placebo. Furthermore, 5 mg 
and 50 mg of opicapone significantly increased the on-time without or with non-
troublesome dyskinesia, and no dose increased on-time with troublesome dyskinesia 
comparing with placebo. The three opicapone doses generated a statistically 
significant difference in the patients global assessment of change comparing to 
placebo, and 50mg opicapone dose generated statistic difference comparing with 
entacapone. No changes were observed for Unified Parkinson’s Disease Rating Scale 
(UPDRS) scores, 39-item Parkinson’s Disease Questionnaire (PDQ-39), Parkinson’s 
Disease Sleep Scale (PDSS) and Non-Motor Symptoms Scale (NMSS). Global 
assessment of change evaluated by the investigators showed a significant overall 
improvement for the 25mg and 50mg compared with placebo and, for the 50mg 
compared with entacapone.[51]  
In BIPARK-II study both opicapone doses decreased the off-time comparing with 
placebo (1.7 hours for 25mg, 2.0 hour for 50mg and 1.1 hour for placebo) but only the 
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greater dose achieved statistical significance. Mean increase in absolute on-time 
without or with non-troublesome dyskinesia was considerably greater with either dose 
of opicapone comparing with placebo (1.4 hours for 25mg, 1.43 hours for 25 mg, 0.8 
hours for placebo), although not statistically significant, as was the total daily on-time 
with troublesome dyskinesia. Comparing with placebo, the change from baseline in 
percentage reduction of off-time, the off-time responders and the on-time responders 
were statistically significant in both intervention arms. [52]  
In the open label phase of BIPARK-II, where almost 98% of the patients randomized 
in the blinded-phase were included, similar motor and non-motor efficacy results 
were achieved.[53, 54] 
The post-hoc pooled analysis of BIPARK I and II participants over 70 years old 
confirmed opicapone’s efficacy in this subgroup of patients.[55] A further pooled 
analysis evaluated the effect of concomitant use of opicapone and dopamine agonists 
and Mao-B inhibitors. It was shown that these two classes of drug do not interfere 
with opicapone’s efficacy.[56] 
 
h. Safety and tolerability 
Phase 1 studies disclosed no tolerability or safety issues among single or multiple 
doses of opicapone.[45, 46, 47] A further study showed that opicapone 50mg 
concentrations increase significantly in patients with moderate hepatic impairment 
(Child-Pug B) due to decrease clearance, but no significant adverse events were 
reported, leading to the conclusion that no dose adjustment is needed in this 
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population.[57] Opicapone does not increase QTc interval, neither in a therapeutic 
dose (50mg) nor in a supratherapeutic dose (800mg).[58] 
Ferreira et al., 2015 trial did not bring up any tolerability or security issues [48]. 
In BIPARK-I, adverse events more frequent in opicapone arms that in placebo were 
dyskinesia (12.4% versus 4.1%), insomnia (4.5% versus 0.8%) and dizziness (3.1% 
versus 0.8%). Opicapone and entacapone had similar profiles, in exception to 
dyskinesia that was more common with opicapone (12.4% versus 8.2%) and to nausea 
and falls that were more common with entacapone (2.2% versus 6.6% and 2.0% 
versus 4.1%, respectively). For opicapone, there was no dose-response relation as far 
as adverse events were concerned.[51] 
In BIPARK-II, 70.4% of subjects in 25mg opicapone, 69.3% of subjects in 50mg and 
61.0% of subjects in placebo group reported at least one adverse event. The most 
frequent adverse events in the treatment arms were dyskinesia, dry mouth, insomnia, 
constipation and blood CPK increase, all significantly higher than in the placebo 
group. It is noteworthy that insomnia was only higher in the 25 mg arm and blood 
CPK increase in the 50mg arm.[52]. The proportion of withdrawals was superior in 
the 50 mg arm (17%), comparing with the 25 mg arm (8%) and the placebo arm 
(10%). 
The open-phase of BIPARK II did not revealed any new or unexpected adverse 
events. Expected adverse events frequencies were consistent with what was found on 
the blinded-phase. The drop-outs rate was low and there was no association with liver 
dysfunction and diarrhea.[59] 
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The post-hoc pooled analysis of BIPARK I and II participants over 70 years old 
confirmed opicapone’s safety. Nevertheless, the proportion of patients with 
hallucinations and weight loss slightly increased in this age group.[55] Another 
pooled analysis proved that no clinically relevant association can be drawn between 
opicapone and hepatobiliary dysfunction.[60] From a similar approach, it was also 
possible to determine that opicapone is not associated with electrocardiographic 
changes, including QT interval widening.[61] 
 
i. Regulatory affairs 
The proprietary of opicapone, BIAL, received market authorization in the European 
Union by the European Medication Agency in June 2016.    
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8. Conclusion 
Opicapone (Ongentys®), a third generation COMT inhibitor also known as BIA 9-
1067, was laboratory-tailored to attain a higher and longer inhibitory potency than 
tolcapone and entacapone. Clinical trials were able to prove opicapone’s safety and 
superiority comparing to placebo. 
Opicapone is a once a day, orally-administrated, peripheral acting, COMT inhibitor 
that yields a marked and sustained inhibitory effects. Has a first order kinetics, take 
1.5-4 hours to reach peak plasma concentrations and a half-life of 0.9 to 1.6 hours. 
The duration of effect is independent of the plasma half-life and largely exceeds 24 
hours. It is metabolized via hepatic sulfation and elimination is exclusively done by 
biliary excretion. Opicapone optimizes L-dopa pharmacokinetic profile to a larger 
extent than entacapone. 
Phase II and III clinical trials showed that opicapone is safe and well tolerated, even 
after long-term administration and in older groups of patients, which effectively 
reduces the OFF-time when used as an add-on intervention to L-dopa in PD patients 
with motor fluctuations. 
The most frequent adverse events are dyskinesia. No dose adjustment is need in liver 
and kidney failure. 
 
 
9. Expert opinion 
Before the opicapone development, there was a gap in the therapeutic option as far as 
COMT inhibitors were concerned. Entacapone is a mildly effective drug and requires 
multiple daily administrations and tolcapone, although more efficacious, it is reserved 
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as a second line drug due to its potentially severe side effects and need for frequent 
monitoring. Opicapone was designed to match available COMT inhibitors efficacy 
and safety profile. 
In the completed clinical trials, 50mg of opicapone once daily achieved at least 1-hour 
OFF-time reduction compared to placebo. Results versus entacapone for both 
investigators and patients global assessment of change suggest also a tendency for a 
better response with opicapone. 
Evidence is still lacking to draw conclusions on how opicapone compares to other 
non-COMT inhibitor options available in the market and licensed for motor 
fluctuations in PD patients. Only further head to head trials will respond to this 
question. 
In the meantime, the use of this new compound is expected to expand the 
armamentarium to treat motor complications, due to its proven efficacy, safety profile 
and administration regimen. 
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10. Drug summary box 
Drug name (generic)  Opicapone 
Phase (for indication under discussion)  Phase III 
Indication (specific to discussion)  Parkinson’s disease patients with motor fluctuations 
Pharmacology description/mechanism of 
action  
COMT inhibitor 
Route of administration  Oral 
Chemical structure  
2,5-dichloro-3-[5-(3,4-dihydroxy- 5-nitrophenyl]-1,2,4-oxadiazol-3-
yl)-4,6-dimethylpyri dine 1-oxide 
Pivotal trial(s)  Ferreira et al., 2015, BIPARK-I and BIPARK-II trials 
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11. Figures 
Figure 1 – Opicapone 
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12. Tables 
 
Table 1 – Clinical studies 
Reference Phase Aims Population Intervention Comparator Duration Centers Country 
Almeida et al., 
2013 
I Dose-escalation study 
(tolerability, safety, 
pharmacokinetics and 
pharmacodynamics) 
64 young 
healthy male 
volunteers 
10, 25, 50, 100, 
200, 400, 800 and 
1,200 mg 
opicapone single 
dose 
Inactive 
placebo 
1 day 1 France 
Almeida et al., 
2013 
I Food-effect study 12 healthy 
male 
volunteers 
50mg opicapone  9 days 1 Canada 
Rocha et al., 
2013 
I Dose-escalation, 
repeated dose study 
(tolerability, safety, 
pharmacokinetics and 
pharmacodynamics) 
34 young 
healthy male 
volunteers 
5, 10, 20 or 30mg 
of opicapone 
Inactive 
placebo 
8 days 1 France 
Rocha et al., 
2014 
I L-dopa 
pharmacokinetics 
80 healthy 
volunteers on 
levodopa 
25, 50 and 75 mg 
opicapone once 
daily 
Inactive 
placebo or 
200 mg 
entacapone 
12 days 1 France 
NCT01568034 II Pharmacokinetics, 
tolerability and safety  
10 PD 
patients on 
levodopa and 
with motor 
flactuations 
25, 50, 100 mg 
opicapone single 
dose 
Inactive 
placebo 
3 days 3 Portugal, Romania, Ukraine 
Ferreira et al, 
2015 
(NCT02071810) 
II Tolerability, safety, 
pharmacokinetics, 
pharmacodynamics and 
efficacy  
35 PD 
patients on 
levodopa and 
with motor 
flactuations 
5, 15, 30 mg 
opicapone once 
daily 
Inactive 
placebo 
28 days 7 Romania, Ukraine 
BIPARK-I 
(NCT01568073) 
III Efficacy and safety 
(superiority vs. placebo 
and non-inferiority vs. 
entacapone) 
 
600 PD 
patients on 
levodopa and 
with end-of-
dose motor 
flactuations 
5, 25 and 50 mg 
opicapone once 
daily 
Inactive 
placebo or 
200 mg 
entacapone 
14-15 weeks 130 Austria, Bosnia and Herzegovina, 
Bulgaria, Croatia, Czech 
Republic, France, Germany, 
Hungary, Italy, Latvia, Lithuania, 
Montenegro, Poland, Portugal, 
Romania, Russia, Serbia, 
Slovakia, Spain, and Ukraine 
BIPARK-II 
(NCT01227655) 
III Efficacy and safety 427 PD 
patients on 
levodopa and 
with end-of-
dose motor 
flactuations 
25 and 50 mg 
opicapone once 
daily 
Inactive 
placebo 
14-15 weeks 69 Argentina, Australia, Belgium, 
Chile, Czech Republic, Estonia, 
India, Israel, Korea, 
Russia, South Africa and United 
Kingdom 
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